Financials data is unavailable for this security.
View more
Year on year Zhejiang Huahai Pharmaceutical Co Ltd 's net income fell -28.88% from 1.17bn to 830.47m despite flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 38.57% to 40.79%.
| Gross margin | 61.97% |
|---|---|
| Net profit margin | 12.21% |
| Operating margin | 16.23% |
| Return on assets | 6.01% |
|---|---|
| Return on equity | 13.52% |
| Return on investment | 8.37% |
More ▼
Cash flow in CNYView more
In 2023, Zhejiang Huahai Pharmaceutical Co Ltd did not generate a significant amount of cash. However, the company earned 2.22bn from its operations for a Cash Flow Margin of 26.68%. In addition the company used 1.62bn on investing activities and also paid 644.23m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 5.99 |
|---|---|
| Tangible book value per share | 4.53 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.40 |
|---|---|
| Quick ratio | 0.7919 |
| Total debt/total equity | 0.8473 |
|---|---|
| Total debt/total capital | 0.4541 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -16.67% and -28.75%, respectively. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
| Div yield(5 year avg) | 0.86% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 31.10% |
| EPS growth(5 years) | 48.80 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 2.69 |
More ▼
